GSK presents positive data for AREXVY, its respiratory syncytial virus ...
WEBGSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in …
GSK says RSV vaccine protects against disease over three seasons
WEB1 day ago · Dive Brief: Vaccine maker GSK unveiled new data Tuesday showing its respiratory syncytial virus vaccine Arexvy protected older adults over three seasons against disease caused by infection. Across the entire time period, one dose of Arexvy was 63% effective against RSV broadly, and 67% effective against severe disease, GSK said.
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower …
WEB1 day ago · To date, GSK has tallied more than 9 million doses of Arexvy being administered since its original approval last year. The shot holds the lion’s share of the RSV vaccine market in the U.S.
GSK RSV shot 43% effective against severe disease in third year
WEB1 day ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus ...
WEB1 day ago · In May 2023, AREXVY was first approved by the US FDA for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. Since then, the vaccine has also been approved for the prevention of RSV-LRTD in individuals 60 years of …
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show...
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US …
WEBFeb 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.